Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346113 | 0.79 | CA12 (0.40) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL2782984 | 0.76 | CA12 (0.39) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL465345 | 0.72 | CA12 (0.37) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL29412545 | 0.72 | GRIA2 (0.33) | CA12CA1CA2CA9GPR3 | |
| SCHEMBL16690044 | 0.72 | GPR3 (0.30) | GPR3 | |
| SCHEMBL560870 | 0.68 | GPR3 (0.37) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL2763395 | 0.68 | RAB9A (0.37) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL9662361 | 0.67 | MEN1 (0.44) | CA12CA1CA2CA9RAB9A | |
| SCHEMBL3420298 | 0.65 | CA12 (0.42) | CA12CA1CA2CA9GPR3 | |
| SCHEMBL12601427 | 0.65 | GPR3 (0.34) | GPR3ALDH1A1MEN1KMT2ANOX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | claimed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | claimed |
| US-6746807-B1 | COLOR PHOTOTHERMOGRAPHIC IMAGING ELEMENT COMPRISING FILTER DYE WHICH UNDERGOES EFFICIENT AND IRREVERSIBLE THERMAL BLEACHING DURING THERMAL PROCESSING AT LOWER TEMPERATURES | EASTMAN KODAK COMPANY | 2004-06-08 | — | — | US | claimed |
| US-20040096758-A1 | THERMALLY BLEACHABLE FILTER DYE COMPOSITIONS COMPRISING BENZOTHIAZINE-DIOXIDE ARYLIDENE DYES AND BASE PRECURSORS FOR USE IN A PHOTOTHERMOGRAPHIC ELEMENT | EASTMAN KODAK COMPANY | 2004-05-20 | — | — | US | claimed |
| US-6140033-A | SUPPORT WITH SILVER HALIDE EMULSIONS WITH COUPLERS | EASTMAN KODAK COMPANY (US) | 2000-10-31 | — | — | US | claimed |
| EP-1014185-A1 | Photographic element, pyrazolazole coupler, method for it's preparation and an azomethine dye | EASTMAN KODAK COMPANY (US) | 2000-06-28 | — | — | EP | claimed |
| CN-1258021-A | Photographic material | EASTMAN KODAK CO (US) | 2000-06-28 | — | — | CN | claimed |
| EP-0413051-B1 | Benzothiazine-1,1-dioxide derivatives | NIPPON HYPOX LAB INC (JP) | 1995-03-15 | — | — | EP | claimed |
| US-5004742-A | Enzyme inhibitors | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 1991-04-02 | — | — | US | claimed |
| EP-0413051-A1 | Benzothiazine-1,1-dioxide derivatives | NIPPON HYPOX LABORATORIES INCORPORATED (JP) | 1991-02-20 | — | — | EP | claimed |
| US-4294961-A | REMOVAL OF METALS | HENKEL CORPORATION (US) | 1981-10-13 | — | — | US | claimed |
| JP-1149781-A | — | — | None | — | — | JP | disclosed |
| JP-1228975-A | — | — | None | — | — | JP | disclosed |
| WO-2024123716-A1 | KCNT1 INHIBITORS COMPRISING A SULFONAMIDE RING CORE AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| CN-113735795-B | Organic room temperature phosphorescent material with multiple stimulus responses, preparation method and application | 天津大学 | 2023-11-10 | — | — | CN | disclosed |
| US-4294961-A | REMOVAL OF METALS | HENKEL CORPORATION (US) | 1981-10-13 | — | — | US | disclosed |
| US-RE29668-E | 4-OXO-1,2-BENZOTHIAZINE-3-CARBOXAMIDE, 1,1-DIOXIDES, ANTIINFLAMMATORY | PFIZER INC. (US) | 1978-06-13 | — | — | US | disclosed |
| US-RE29669-E | CYCLIZATION OF GLYCINEAMIDES | PFIZER, INC. (US) | 1978-06-13 | — | — | US | disclosed |
| US-3971802-A | ANTIINFLAMMATORY | PFIZER INC. (US) | 1976-07-27 | — | — | US | disclosed |
| US-3925371-A | Benzothiazine-1,1-dioxides | MCNEILAB INC | 1975-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | CA12 4249/4885CA1 1255/4885CA2 680/4885 |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | CA12 3436/4885CA1 1063/4885CA2 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.